(MENAFN– GlobeNewsWire – Nasdaq)
VANCOUVER, British Columbia, Jan. 28, 2022 (GLOBE NEWSWIRE) — THC BioMed Intl (CSE:THC) (OTCQX:THCBF) (FSE:TFHD), one of Canada’s oldest licensed producers of medical and recreational cannabis, has been granted a license by an overseas government to cultivate cannabis for medical and scientific use. With its cultivation and production based in Kelowna, B.C., including a proprietary extraction system, THC was first licensed to deal with cannabis in 2013 under a Health Canada Section 56 exemption under the Controlled Drugs and Substances Act and has been a Licensed Producer under the current regime since 2016.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on“InvestmentPitch.com” and on“YouTube”. If these links are not enabled, please visit and enter“THC BioMed” in the search box.
The company’s product focus is on high-quality, high-potency products including dry flower, edibles, beverages, pre-rolls along with a number of genetic strains which it sells to Canada’s medical and recreational cannabis markets.
John Miller, President and CEO, stated:“Since March 2020, we have been looking into the possibilities and challenges of carrying out an R&D program in relation…
Original Author Link click here to read complete story..
(MENAFN– GlobeNewsWire – Nasdaq)
VANCOUVER, British Columbia, Jan. 28, 2022 (GLOBE NEWSWIRE) — THC BioMed Intl (CSE:THC) (OTCQX:THCBF) (FSE:TFHD), one of Canada’s oldest licensed producers of medical and recreational cannabis, has been granted a license by an overseas government to cultivate cannabis for medical and scientific use. With its cultivation and production based in Kelowna, B.C., including a proprietary extraction system, THC was first licensed to deal with cannabis in 2013 under a Health Canada Section 56 exemption under the Controlled Drugs and Substances Act and has been a Licensed Producer under the current regime since 2016.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on“InvestmentPitch.com” and on“YouTube”. If these links are not enabled, please visit and enter“THC BioMed” in the search box.
The company’s product focus is on high-quality, high-potency products including dry flower, edibles, beverages, pre-rolls along with a number of genetic strains which it sells to Canada’s medical and recreational cannabis markets.
John Miller, President and CEO, stated:“Since March 2020, we have been looking into the possibilities and challenges of carrying out an R&D program in relation…